Ugur Sahin
September 10, 2019 06:29 AM EDTUpdated 10:42 AM
Financing

Fresh off the heels of mega fi­nanc­ing round, Ger­many's BioN­Tech makes $100M US IPO play

Natalie Grover

Reporter

Two months af­ter one of the largest sin­gle pri­vate fund­ing rounds for a biotech com­pa­ny in Eu­ro­pean his­to­ry, Ger­man can­cer drug de­vel­op­er BioN­Tech is gun­ning for a $100 mil­lion US IPO.

Hel­mut Jeg­gle
Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times